Exchange Traded Concepts LLC Grows Holdings in Cencora, Inc. $COR

Exchange Traded Concepts LLC grew its position in Cencora, Inc. (NYSE:COR) by 312.7% in the third quarter, HoldingsChannel reports. The fund owned 10,458 shares of the company’s stock after acquiring an additional 7,924 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Cencora were worth $3,268,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of COR. Atlantic Edge Private Wealth Management LLC increased its position in shares of Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after buying an additional 35 shares in the last quarter. Grove Bank & Trust boosted its position in shares of Cencora by 4.3% during the 2nd quarter. Grove Bank & Trust now owns 879 shares of the company’s stock valued at $264,000 after acquiring an additional 36 shares during the last quarter. Quadcap Wealth Management LLC grew its holdings in shares of Cencora by 1.5% in the second quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock valued at $722,000 after purchasing an additional 36 shares during the period. U.S. Capital Wealth Advisors LLC increased its position in Cencora by 0.4% during the second quarter. U.S. Capital Wealth Advisors LLC now owns 8,547 shares of the company’s stock worth $2,563,000 after purchasing an additional 38 shares during the last quarter. Finally, Monument Capital Management raised its position in shares of Cencora by 2.4% during the 2nd quarter. Monument Capital Management now owns 1,637 shares of the company’s stock valued at $491,000 after buying an additional 38 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on COR shares. JPMorgan Chase & Co. upped their price target on Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. Barclays started coverage on shares of Cencora in a research note on Monday, December 8th. They set an “overweight” rating and a $400.00 target price for the company. TD Cowen boosted their price target on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Mizuho upped their price objective on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Finally, Evercore ISI set a $400.00 price objective on shares of Cencora and gave the stock an “outperform” rating in a research report on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Cencora has a consensus rating of “Moderate Buy” and an average price target of $373.25.

Cencora Price Performance

Cencora stock opened at $343.17 on Friday. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32. Cencora, Inc. has a 52-week low of $223.92 and a 52-week high of $377.54. The firm has a market cap of $66.57 billion, a PE ratio of 43.17, a price-to-earnings-growth ratio of 1.62 and a beta of 0.63. The company’s 50 day moving average is $348.33 and its two-hundred day moving average is $314.46.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. The business had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The company’s revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date was Friday, November 14th. This is a boost from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio (DPR) is 30.19%.

Insider Transactions at Cencora

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the transaction, the executive vice president owned 23,891 shares in the company, valued at $8,173,111.10. The trade was a 12.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the sale, the chief executive officer directly owned 37,940 shares in the company, valued at approximately $12,398,792. This represents a 11.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 20,317 shares of company stock valued at $7,009,260. 10.80% of the stock is currently owned by corporate insiders.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.